Skip to main content
PLOS One logoLink to PLOS One
. 2020 Sep 25;15(9):e0239273. doi: 10.1371/journal.pone.0239273

Genomic analysis of cardiac surgery-associated Mycobacterium chimaera infections in Italy

Arash Ghodousi 1, Emanuele Borroni 1, Marta Peracchi 2, Giorgio Palù 3, Loredana Fallico 4, Mario Rassu 4, Vinicio Manfrin 4, Paola Mantegani 1, Vincenzina Monzillo 5, Riccardo Manganelli 3, Enrico Tortoli 1, Daniela Maria Cirillo 1,*
Editor: Egon Anderson Ozer6
PMCID: PMC7518601  PMID: 32976495

Abstract

One hundred and twenty-two Mycobacterium chimaera strains isolated in Italy from cardiac surgery-related patients, cardiac surgery-unrelated patients and from heater-cooler units, were submitted to whole-genome sequencing and to subsequent SNP analysis. All but one strains isolated from cardiac surgery-related patients belonged to Subgroup 1.1 (19/23) or Subgroup 1.8 (3/23). Only 28 out of 79 strains isolated from heater-cooler units belonged to groupings other than 1.1 and 1.8. The strains isolated from cardiac surgery-unrelated patients were instead distributed across the phylogenetic tree. Our data, the first on isolates from Italy, are in agreement with a recent large genomic study suggesting a common source, represented by strains belonging to Subgroups 1.1 and 1.8, of cardiac surgery-related Mycobacterium chimaera infections. The strains belonging to groupings other than 1.1 and 1.8 isolated from heather-cooler units evidently resulted from contaminations at hospital level and had no share in the Mycobacterium chimaera outbreak. One Mycobacterium chimaera strain investigated in this study proved distant from every previously known Mycobacterium chimaera Groups (1, 2, 3 and 4) and we propose to assign to a novel group, named “Group 5”.

Introduction

A global outbreak of Mycobacterium chimaera (M. chimaera) infections associated with open heart cardiac surgery is ongoing. Since 2013, when the first cases, dated back to 2011, were discovered [1] more than 140 cases of severe M. chimaera infection have been identified worldwide in patients who had undergone cardiothoracic surgery with extracorporeal circulation [2]. Very early it emerged that the specific heater-cooler units (HCUs) used in the operatory rooms were contaminated by M. chimaera and likely represented the source of infection [3]. Whole genome sequencing (WGS) of M. chimaera strains isolated from patients and HCUs of a specific brand and model (Livanova 3T, Germany), both in hospitals and at the factory, has revealed high level of genetic similarity making the most plausible hypothesis a point source contamination of the devices during manufacture [4].

Very little is known about the relation of the Italian clinical and environmental isolates to the global epidemic.

We report here the results of WGS analysis conducted on 122 M. chimaera isolates from cardiac surgery (CS) related and unrelated patients and from HCUs in different centres in Italy.

Materials and methods

A total of 122 Italian isolates of M. chimaera were included in this study; 79 from HCUs and 43 from patients, collected between 2015–2019. All clinical M. chimaera isolates were received from different hospitals together with medical records of the patients. All the isolates and the patients’ medical reports were totally anonymized before our access. A written informed consent to publish the data was obtained from all involved hospitals.

Among the 43 patients, 23 had a history of cardiothoracic surgery (CS-related) and 15 had never undergone open-heart surgery (CS-unrelated). For five additional patients no information was available confirming or excluding previous open-heart surgery.

In order to compare our isolates with those already reported as part of the global epidemic we included five published environmental isolates from water supply and from new built 3T-HCUs at LivaNova production site (n = 2; Subgroup 1.8; GenBank accession nos. ERR1463901, ERR1463898), 3T-HCUs in use in Switzerland (n = 2; Subgroup 1.1 and Branch 1; GenBank accession nos. ERR1464041, ERR1463965) and at Maquet (Rastatt, Germany) HCU production site (n = 1; Subgroup 1.8; GenBank Accession no. ERR1464127).

WGS was performed on the Illumina NextSeq 500 platform and the reads were mapped on M. chimaera DSM-44623 as reference genome (GenBank accession no. LQOO00000000) using Burrows-Wheeler Aligner [5]. All datasets reached a mean coverage >50 fold, with at least 80% of the reference genomes positions complying with the thresholds of variant detection (minimum depth of coverage of 10x and 75% allele frequency). Variant calling was done using the widely employed programs Samtools [6] and the Genome Analysis Toolkit (GATK) [7].Custom perl scripts were used to filter the variants with a minimum coverage of 10 reads in both forward and reverse orientation, 10 reads calling the allele with a phred score of ≥20, and 75% allele frequency. The combined set of detected high quality SNP positions was used to construct a Maximum parsimony tree using RAxML version 8 [8] with a general time reversible substitution model, 1,000 re-samples and Gamma20 likelihood optimization to account for rate heterogeneity among sites. The resulting phylogenetic tree was then visualized and annotated using the online program GrapeTree [9].

In order to detect the mixed populations in the samples we reduced the threshold of variant detection (at least 2 reads calling the allele with a phred score of ≥20 and 5% allele frequency).

Average Nucleotide Identity (ANI) were calculated based on OrthoANIu algorithm [10], using M. chimaera DSM-44623 as reference genome. Clustal W/X software were used for multiple sequence alignment of the sequences [11] and subsequent calculation of phylogenetic networks and visualization were done with SplitsTree V4.16.1 [12]

Single genomes were located to Groups, Subgroups and Branches in the basis of signature SNPs described previously [4]. Non-Group 1 and mixed genomes with the major subpopulation < 75% were excluded from phylogenetic analysis (n = 19 genomes).

Results and discussion

Out of 122 genomes only three belonged to groups other than Group 1. Their distribution among the different groupings is as reported in Table 1.

Table 1. Group/subgroup distribution of M. chimaera isolates in the present study.

HCU CS-related patients CS-unrelated patients CS-unknown patients
Subgroup 1.1 44 19 2 2
Branch 1 7 1 8 3
Subgroup 1.8 7 3
Branch 2 2
Group 1. ungrouped 2
Group 2 2
Group 5* 1
Subgroups 1.1+1.8 10
Subgroup 1.1+Branch 1 4
Other Mixes 5
Total 79 23 15 5

The group/subgroups were assigned based on the specific SNP signatures [4].

*Found in this study

All M. chimaera isolates from CS-related patients fitted Group 1; of these, 19 belonged to Subgroup 1.1, three to Subgroup 1.8 and one to Branch 1. Subgroups 1.1 and 1.8 were also the most frequent among the HCU isolate with 44 and 7 isolates, respectively. Moreover from 10 HCUs a mixed population of M. chimaera from Subgroups 1.1 and 1.8 were isolated (Tables 1 and S1). WGS analysis confirmed nine isolates from HCUs and one from a CS-related patient, all belonging to Subgroup 1.1, were identical to one strain isolated from HCU in Switzerland [4]. Furthermore, four of our isolates belonging to Subgroup 1.8, isolated from HCUs (n = 2) and CS-related patients (n = 2), were closely related (3–4 SNPs different) to the strains grown from water supply and 3T-HCU at LivaNova production site [3].

A common source of M. chimaera infection has been recognized on the basis of the remarkable similarity between almost all the isolates from patients with a history of cardiac surgery and the ones recovered from most HCUs [4,13]. Three distinct strains of M. chimaera, belonging to Subgroups 1.1, 1.8, and 2.1, have been reported responsible of contamination of LivaNova HCUs at the production site [4]. This finding is in agreement with our results showing large prevalence of Subgroups 1.1 and 1.8 among the isolates from CS-related patients and HCUs (Fig 1). Only in one CS-associated patient we isolated M. chimaera belonging to Branch 1; this strain was isolated from a sputum sample and the patient did not present any of signs or symptoms related to deep infection by M. chimaera.

Fig 1. Maximum parsimony tree built from 348 SNP positions of the 108 group1 isolates mapped to the genome of M. chimaera DSM44623 in logarithmic scale.

Fig 1

The M. chimaera genomes from HCUs, patients and Published genome data are indicated in different colours. The two major outbreak subgroups 1.1, 1.8 and also other subgroups are indicated by red labels. A cut-off of 5 SNPs was used to collapse the branches. For this analysis, we combined all group 1 isolates from our study with five other published genomes from LivaNova HCUs, water supply at production site and Maquet HCU production site. We excluded isolates for which a mixed strain population was detected based on signature SNPs [4].

The isolates from CS-unrelated patients were distributed across the phylogenetic tree, mostly belonging to Branch 1. Overall, the isolates within Subgroup 1.1 showed comparatively little diversity, with a median pairwise distance of only 4 SNPs (range 0–20). These results are in agreement with clonal M. chimaera isolates, described in HCU water samples and CS-related patient from Australia, New Zealand and also US patient strains [14,15]. Unaccountably, two isolates from two CS-unrelated patients, in different hospitals, grouped with Subgroup 1.1 and were genetically very similar to those from CS-related patients and HCUs (mean pairwise distance of <5 SNPs).

A very peculiar M. chimaera strain was isolated from lower respiratory infection in a CS-unrelated patient. The INNO-LiPA MYCOBACTERIA v.2 line-probe assay ascribed the strain to the Mycobacterium avium complex. Sequencing of the full 16S rRNA gene and the 16S–23S ITS identified the bacterium as M. chimaera. The value of ANI (98,53% identity) definitively confirmed that our strain and M. chimaera DSM-44623 belonged to the same species. Alignment of concatenated SNPs of our isolate and those of the four known M. chimaera groups performed by using clustal W/X software and subsequent visualization with SplitsTree software confirmed the phylogenetic position of all the genomes within the Mycobacterium avium complex, most closely related to M. chimaera. Interestingly, using the suggested threshold of 1000 SNPs for defining M. chimaera groups [4], the strain proved different from all four known groups, with the groups 1, 2, 3 and 4 being 23793, 6837, 9431 and 23818 SNPs distant respectively (Fig 2).

Fig 2. NeighborNet splitstree tree.

Fig 2

NeighborNet splitstree tree built from 60570 SNP positions of representative M. chimaera genomes belonging to Groups 1, 2, 3 and 4, supporting the presence of a previously unreported grouping we named Group 5.

Present study has some limitations related to the partial coverage of the Italian M. chimaera epidemic and to lack of epidemiological data linking individual patients to specific HCUs.

Conclusions

In conclusion, our data are consistent with the hypothesis that disseminated M. chimaera in CS patient are related with the use of a specific HCU; more the similarity of isolates in different part of the world pinpoint a common, single source of infection.

Clinicians should monitor patients who have had cardiac surgery using HCUs for signs and symptoms of M. chimaera infection to enable early diagnosis and treatment. Finally, we shown that WGS is the preferred method to distinguish whether a clinical strain is related to the HCU outbreak strain.

All sequence reads were submitted to the NCBI sequence read archive with Project number PRJNA592124 (S1 Table).

Supporting information

S1 Table

(XLSX)

Data Availability

All sequence reads were submitted to the NCBI Sequence Read Archive (Project number PRJNA592124).

Funding Statement

The authors received no specific funding for this work.

References

  • 1.Achermann Y, Rössle M, Hoffmann M, Deggim V, Kuster S, Zimmermann DR, et al. Prosthetic Valve Endocarditis and Bloodstream Infection Due to Mycobacterium chimaera. J Clin Microbiol. 2013. June 1;51(6):1769 10.1128/JCM.00435-13 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Campins Marti M, Borras Bermejo B, Armadans Gil L. Infections with Mycobacterium chimaera and open chest surgery. An unresolved problem. Med Clin (Barc). 2019. April 18;152(8):317–23. [DOI] [PubMed] [Google Scholar]
  • 3.Sax H, Bloemberg G, Hasse B, Sommerstein R, Kohler P, Achermann Y, et al. Prolonged Outbreak of Mycobacterium chimaera Infection After Open-Chest Heart Surgery. Clinical Infectious Diseases. 2015. March 11;61(1):67–75. 10.1093/cid/civ198 [DOI] [PubMed] [Google Scholar]
  • 4.Ingen J van, Kohl TA, Kranzer K, Hasse B, Keller PM, Szafrańska AK, et al. Global outbreak of severe Mycobacterium chimaera disease after cardiac surgery: a molecular epidemiological study. The Lancet Infectious Diseases. 2017;17(10):1033–41. 10.1016/S1473-3099(17)30324-9 [DOI] [PubMed] [Google Scholar]
  • 5.Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform. Bioinformatics. 2009. July 15;25(14):1754–60. 10.1093/bioinformatics/btp324 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009. August 15;25(16):2078–9. 10.1093/bioinformatics/btp352 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Research. 2010. September 1;20(9):1297–303. 10.1101/gr.107524.110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Stamatakis A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large phylogenies. Bioinformatics. 2014;30(9):1312–3. 10.1093/bioinformatics/btu033 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Zhou Z, Alikhan N-F, Sergeant MJ, Luhmann N, Vaz C, Francisco AP, et al. GrapeTree: visualization of core genomic relationships among 100,000 bacterial pathogens. Genome Research. 2018;28(9):1395–404. 10.1101/gr.232397.117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Yoon S-H, Ha S-M, Lim J, Kwon S, Chun J. A large-scale evaluation of algorithms to calculate average nucleotide identity. Antonie Van Leeuwenhoek. 2017. October;110(10):1281–6. 10.1007/s10482-017-0844-4 [DOI] [PubMed] [Google Scholar]
  • 11.Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, et al. Clustal W and Clustal X version 2.0. Bioinformatics. 2007. November 1;23(21):2947–8. 10.1093/bioinformatics/btm404 [DOI] [PubMed] [Google Scholar]
  • 12.Huson DH, Bryant D. Application of Phylogenetic Networks in Evolutionary Studies. Molecular Biology and Evolution. 2005. October 12;23(2):254–67. 10.1093/molbev/msj030 [DOI] [PubMed] [Google Scholar]
  • 13.Zhang X, Lin J, Feng Y, Wang X, McNally A, Zong Z. Identification of Mycobacterium chimaera in heater-cooler units in China. Scientific Reports. 2018. May 18;8(1):7843 10.1038/s41598-018-26289-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Hasan NA, Epperson LE, Lawsin A, Rodger RR, Perkins KM, Halpin AL, et al. Genomic Analysis of Cardiac Surgery-Associated Mycobacterium chimaera Infections, United States. Emerg Infect Dis. 2019. March;25(3):559–63. 10.3201/eid2503.181282 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Williamson D, Howden B, Stinear T. Mycobacterium chimaera Spread from Heating and Cooling Units in Heart Surgery. N Engl J Med. 2017. February 9;376(6):600–2. 10.1056/NEJMc1612023 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Egon Anderson Ozer

17 Jul 2020

PONE-D-20-09309

Genomic Analysis of Cardiac Surgery-Associated Mycobacterium chimaera Infections in Italy

PLOS ONE

Dear Dr. Cirillo,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

My apologies for the delayed response. More than one reviewer accepted the assignment but did not return a review. The person who completed a review had a very favorable impression of the manuscript and I agree based on my own review that it is a strong manuscript that requires only some minor modifications and clarifications. In addition to addressing the reviewer's comments below, please see my own review comments here:

  • Line 64: Please clarify whether "10-fold coverage" means coverage by at least 10 reads or something else.

  • Line 64: Please provide more detail of the settings used for variant calling in samtools and GATK.

  • Line 69: Typo: should be "GrapeTree"

  • Line 70: Minimum 2-fold (or read?) coverage seems like it would identify many sequencing errors as false-positive variants. What steps were taken to ensure this was not the case?

  • Line 88: The term "very similar" should be more specifically defined or quantified.

  • Line 100: Should define the abbreviations used in the figure (i.e. "P. data") in the figure legend for clarity.

  • Line 113: Describe how ANI was determined

  • Line 114: Clustal X and SplitsTree4 should be referenced and discussed in the materials and methods section.

  • Line 131: A supplemental table listing the isolates sequenced, their group assignments, and SRA accession numbers should be added.

  • Line 166: The PLoS One editorial office will be following up with you re: further clarification of the Ethics Statement.

Thank you for your patience in these difficult and unusual times.

Please submit your revised manuscript by Aug 31 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Egon Anderson Ozer, MD PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your ethics statement in the Methods and online submission information, please ensure that you have specified whether patient samples are de-identified or anonymized before access.

3. Your ethics statement must appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please also ensure that your ethics statement is included in your manuscript, as the ethics section of your online submission will not be published alongside your manuscript.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Excellent and concise analysis of the M.chimaera associated with HCU in the authors' country (Italy). The statistical details of the analyses were a bit low. Why use the type strain DSM 44623T versus ZUERICH1 or CDC 2015-22-71 as references for the mapping of the reads? The application of published SNP thresholds is appropriate, but the distribution and depiction of the SNP variation observed in HCU isolates from Italy is absent. Percentages of HCU clone versus non-related genotypes were absent from the text as well. Just a few more statistical numbers included in the report would be appropriate. A table or supplementary table of isolates, name, origin, and SRA or biosample number should be included in Supplementary materials for readers. Authors omitted citing the two HCU genomic analyses from the US CDC/National Jewish Health and the genomic analyses of Australian/New Zealand isolates.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2020 Sep 25;15(9):e0239273. doi: 10.1371/journal.pone.0239273.r002

Author response to Decision Letter 0


28 Aug 2020

Response to Editor and Reviewers:

Editor# Line 64: Please clarify whether "10-fold coverage" means coverage by at least 10 reads or something else.

Thanks for the comment. We have re-wrote the phrases to clarify “10-fold coverage”.

Line 64: Please provide more detail of the settings used for variant calling in samtools and GATK.

Thanks for the comment. More details of the setting for variant calling were added to the manuscript.

Line 69: Typo: should be "GrapeTree"

It is now corrected.

Line 70: Minimum 2-fold (or read?) coverage seems like it would identify many sequencing errors as false-positive variants. What steps were taken to ensure this was not the case?

We’d like to thank for this comment. In this case we have used the parameters in which the majority allele other than wild type is considered per position. For each isolate, we calculated the mean allele frequency for each set of SNP alleles, setting the following thresholds: minimum mapping quality of 20, minimum base quality at a position of 20, minimum read depth at a position of 2X, maximum strand bias for a position 90% in order to distinguish the real genomic variants from possible sequencing errors.

Line 88: The term "very similar" should be more specifically defined or quantified.

Thanks for the comment, the mentioned term was defined more specifically in the text.

Line 100: Should define the abbreviations used in the figure (i.e. "P. data") in the figure legend for clarity.

The figure legend has been corrected.

Line 113: Describe how ANI was determined

The calculation of ANI has been described in Materials & Methods section.

Line 114: Clustal X and SplitsTree4 should be referenced and discussed in the materials and methods section.

Thanks for the comment. Clustal X and SplitsTree4 have been referenced and discussed in the materials and methods section.

Line 131: A supplemental table listing the isolates sequenced, their group assignments, and SRA accession numbers should be added.

Thank you for this comment. A supplementary table listing the isolates sequenced, their group assignment, and SRA accession numbers has been added and submitted with the revised manuscript.

Line 166: The PLoS One editorial office will be following up with you re: further clarification of the Ethics Statement.

Reviewer #1: Excellent and concise analysis of the M.chimaera associated with HCU in the authors' country (Italy). The statistical details of the analyses were a bit low. Why use the type strain DSM 44623T versus ZUERICH1 or CDC 2015-22-71 as references for the mapping of the reads? The application of published SNP thresholds is appropriate, but the distribution and depiction of the SNP variation observed in HCU isolates from Italy is absent. Percentages of HCU clone versus non-related genotypes were absent from the text as well. Just a few more statistical numbers included in the report would be appropriate. A table or supplementary table of isolates, name, origin, and SRA or biosample number should be included in Supplementary materials for readers. Authors omitted citing the two HCU genomic analyses from the US CDC/National Jewish Health and the genomic analyses of Australian/New Zealand isolates.

Response:

We would like to thank the reviewer for the comment. In order to analyze the WGS data we have used the M. chimaera DSM 44623 and also M. chimaera strain Zuerich1 as reference genome and we didn’t find significant differences for phylogenetic analysis. However, genome size of M. chimaera DSM 44623 and strain Zuerich1 are different (5,865,644 vs 6,175,731 bp, respectively). For genotyping we extracted a set of variants specific for (sub)groups of isolates defined by the phylogenetic analysis with respect to the M. chimaera DSM 44623 genome and its annotation with reference to van Ingen et al. Lancet Infect Dis 2017;17: 1033–41.

Moreover, a more detailed statistic of HCU and clinical isolates was included the result section.

A supplementary table of isolates, name, origin, and SRA accession number has been included in Supplementary materials.

Finally, the two mentioned papers were cited in the manuscript and included in the references.

Attachment

Submitted filename: Ghodousi et al. rebutal letter-PLOS ONE.docx

Decision Letter 1

Egon Anderson Ozer

3 Sep 2020

Genomic Analysis of Cardiac Surgery-Associated Mycobacterium chimaera Infections in Italy

PONE-D-20-09309R1

Dear Dr. Cirillo,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Egon Anderson Ozer, MD PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for an excellent revised manuscript draft. All of my suggestions and points of review have been addressed.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Acceptance letter

Egon Anderson Ozer

16 Sep 2020

PONE-D-20-09309R1

Genomic Analysis of Cardiac Surgery-Associated Mycobacterium chimaera Infections in Italy

Dear Dr. Cirillo:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Egon Anderson Ozer

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table

    (XLSX)

    Attachment

    Submitted filename: Ghodousi et al. rebutal letter-PLOS ONE.docx

    Data Availability Statement

    All sequence reads were submitted to the NCBI Sequence Read Archive (Project number PRJNA592124).


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES